Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update
- PMID: 23129741
- DOI: 10.1200/JCO.2012.45.9859
Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update
Abstract
Purpose: To provide recommendations on the follow-up and management of patients with breast cancer who have completed primary therapy with curative intent.
Methods: To update the 2006 guideline of the American Society of Clinical Oncology (ASCO), a systematic review of the literature published from March 2006 through March 2012 was completed using MEDLINE and the Cochrane Collaboration Library. An Update Committee reviewed the evidence to determine whether the recommendations were in need of updating.
Results: There were 14 new publications that met inclusion criteria: nine systematic reviews (three included meta-analyses) and five randomized controlled trials. After its review and analysis of the evidence, the Update Committee concluded that no revisions to the existing ASCO recommendations were warranted.
Recommendations: Regular history, physical examination, and mammography are recommended for breast cancer follow-up. Physical examinations should be performed every 3 to 6 months for the first 3 years, every 6 to 12 months for years 4 and 5, and annually thereafter. For women who have undergone breast-conserving surgery, a post-treatment mammogram should be obtained 1 year after the initial mammogram and at least 6 months after completion of radiation therapy. Thereafter, unless otherwise indicated, a yearly mammographic evaluation should be performed. The use of complete blood counts, chemistry panels, bone scans, chest radiographs, liver ultrasounds, pelvic ultrasounds, computed tomography scans, [(18)F]fluorodeoxyglucose-positron emission tomography scans, magnetic resonance imaging, and/or tumor markers (carcinoembryonic antigen, CA 15-3, and CA 27.29) is not recommended for routine follow-up in an otherwise asymptomatic patient with no specific findings on clinical examination.
Similar articles
-
American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting.J Clin Oncol. 2006 Nov 1;24(31):5091-7. doi: 10.1200/JCO.2006.08.8575. Epub 2006 Oct 10. J Clin Oncol. 2006. PMID: 17033037
-
American Society of Clinical Oncology 1998 update of recommended breast cancer surveillance guidelines.J Clin Oncol. 1999 Mar;17(3):1080-2. doi: 10.1200/JCO.1999.17.3.1080. J Clin Oncol. 1999. PMID: 10071303
-
Follow-up after treatment for breast cancer. The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer.CMAJ. 1998 Feb 10;158 Suppl 3:S65-70. CMAJ. 1998. PMID: 9484280 Review.
-
American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline.J Clin Oncol. 2016 Feb 20;34(6):611-35. doi: 10.1200/JCO.2015.64.3809. Epub 2015 Dec 7. J Clin Oncol. 2016. PMID: 26644543 Review.
-
Preventive health care, 1999 update: 3. Follow-up after breast cancer. Canadian Task Force on Preventive Health Care.CMAJ. 1999 Oct 19;161(8):1001-8. CMAJ. 1999. PMID: 10551200 Free PMC article.
Cited by
-
Salivary Transmembrane Mucins of the MUC1 Family (CA 15-3, CA 27.29, MCA) in Breast Cancer: The Effect of Human Epidermal Growth Factor Receptor 2 (HER2).Cancers (Basel). 2024 Oct 12;16(20):3461. doi: 10.3390/cancers16203461. Cancers (Basel). 2024. PMID: 39456554 Free PMC article.
-
Development of a Second Primary Lung Cancer Following a Primary Breast Cancer: A Case Series.J Investig Med High Impact Case Rep. 2024 Jan-Dec;12:23247096241272013. doi: 10.1177/23247096241272013. J Investig Med High Impact Case Rep. 2024. PMID: 39390783 Free PMC article.
-
Blood endocan as a biomarker for breast cancer recurrence.Cancer Biomark. 2024;41(2):145-154. doi: 10.3233/CBM-240034. Cancer Biomark. 2024. PMID: 39331092 Free PMC article.
-
Breast cancer recurrence in relation to mode of detection: implications on personalized surveillance.Breast Cancer Res Treat. 2024 Sep 10. doi: 10.1007/s10549-024-07475-8. Online ahead of print. Breast Cancer Res Treat. 2024. PMID: 39251456
-
Cutaneous Metastasis in Breast Cancer: A Case Report.Am J Case Rep. 2024 Jul 12;25:e943999. doi: 10.12659/AJCR.943999. Am J Case Rep. 2024. PMID: 38992932 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous

